{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-051729","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2024-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.205518+00:00","generated_at":"2026-05-29T02:11:52.788953+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Arrowhead Chairman Dr. Given to retire; Sarepta CEO Ingram expected to join board","bullets":["Dr. Douglass Given retires from Board effective Dec 31, 2024, after 14 years as Chairman.","Douglas S. Ingram, President and CEO of Sarepta Therapeutics, expected to join Board in Q1 2025.","Ingram's appointment aligns with closing of Arrowhead-Sarepta Exclusive License and Collaboration Agreement (Nov 25, 2024).","Company expresses gratitude for Dr. Given's service."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-051729","json":"https://secwatch.observer/filing/0001628280-24-051729.json","markdown":"https://secwatch.observer/filing/0001628280-24-051729.md","text":"https://secwatch.observer/filing/0001628280-24-051729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828024051729/0001628280-24-051729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828024051729/arwr-20241211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:11:52.788953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}